Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family

Neurology

Volumn 84, Issue 22, 2015, Pages 2266-2273

  Conidi, Maria E ^a   Bernardi, Livia ^a   Puccio, Gianfranco ^a   Smirne, Nicoletta ^a   Muraca, Maria G ^a   Curcio, Sabrina A M ^a   Colao, Rosanna ^a   Piscopo, Paola ^b   Gallo, Maura ^a   Anfossi, Maria ^a   Frangipane, Francesca ^a   Clodomiro, Alessandra ^a   Mirabelli, Maria ^a   Vasso, Franca ^a   Cupidi, Chiara ^a   Torchia, Giusi ^a   Di Lorenzo, Raffaele ^a   Mandich, Paola ^c   Confaloni, Annamaria ^b   Maletta, Raffaele G ^a   Bruni, Amalia C ^a   more..

^a ASP Catanzaro   (Turkey)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; APP GENE; ARTICLE; ASYMPTOMATIC DISEASE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONSANGUINEOUS MARRIAGE; CONTROLLED STUDY; FAMILIAL DISEASE; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MIDDLE AGED; MUTATION; PEDIGREE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PEDIGREE;

EID: 84930332203     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001648     Document Type: Article

References (40)

1. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012;33:1340-1344.
2. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38:24-26.
3. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349:704-706.
4. Hendriks L, Van Broeckhoven C. A beta A4 amyloid precursor protein gene and Alzheimer's disease. Eur J Biochem 1996;237:6-15.
5. Rossi G, Giaccone G, Maletta R, et al. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology 2004;63: 910-912.
6. Maat-Schieman ML, van Duinen SG, Bornebroek M, Haan J, Roos RA. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): II: a review of histopathological aspects. Brain Pathol 1996;6:115-120.
7. Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009;323:1473-1477.
8. Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008;63:377-387.
9. Kumar-Singh S, De Jonghe C, Cruts M, et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum Mol Genet 2000;9: 2589-2598.
10. De Jonghe C, Esselens C, Kumar-Singh S, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet 2001; 10:1665-1671.
11. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870.
12. Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71:85-92.
13. Ertekin-Taner N, Younkin LH, Yager DM, et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 2008;70:596-606.
14. Armstrong J, Boada M, Rey MJ, Vidal N, Ferrer I. Familial Alzheimer disease associated with A713T mutation in APP. Neurosci Lett 2004;370:241-243.
15. Bernardi L, Geracitano S, Colao R, et al. AbetaPP A713T mutation in late onset Alzheimer's disease with cerebrovascular lesions. J Alzheimers Dis 2009;17: 383-389.
16. Bernardi L, Geracitano S, Colao R, et al. Late onset Alzheimer's disease with cerebrovascular lesions as a distinctive phenotype of the AbPP A713T mutation in Southern Italy. In: Handbook of Imaging the Alzheimer Brain (Advances in Alzheimer's Disease). Washington, DC: IOS Press; 2011:689.
17. Bernardi L, Maletta RG, Tomaino C, et al. The effects of APOE and tau gene variability on risk of frontotemporal dementia. Neurobiol Aging 2006;27:702-709.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-944.
19. McKeith IG, Galasko D, Kosaka K, et al. Consensus Guidelines International Workshop for the clinical and pathological diagnosis of dementia with Lewy body disease (DLB): report of the Consortium on DLB. Neurology 1996;47:1113-1124.
20. Brun A, Englund B, Gustafson L, et al. Consensus statement: clinical and neuropathological criteria for frontotemporal dementia, J Neurol Neurosurg Psychiatry 1994;57:416-418.
21. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINCSDS-AIREN International Work Group. Neurology 1993;43:250-260.
22. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
23. Hutton M, Busfield F, Wragg M, et al. Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. Neuroreport 1996;7:801-805.
24. Cruts M, van Duijn CM, Backhovens H, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet 1998;7:43-51.
25. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
26. Bernardi L, Gallo M, Anfossi M, et al. Role of TOMM40 rs10524523 polymorphism in onset of Alzheimer's disease caused by the PSEN1 M146L mutation. J Alzheimers Dis 2013;37:285-289.
27. Eckman CB, Mehta ND, Crook R, et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet 1997;6:2087-2089.
28. Prasher VP, Sajith SG, Mehta P, Zigman WB, Schupf N. Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry 2010;25:202-207.
29. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001;21:372-381.
30. Mayeux R, Honig LS, Tang MX, et al. Plasma A[beta] 40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003;61:1185-1190.
31. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000;57:100-105.
32. Park L, Zhou P, Koizumi K, et al. Brain and circulating levels of Ab1-40 differentially contribute to vasomotor dysfunction in the mouse brain. Stroke 2013; 44:198-204.
33. Gomis M, Sobrino T, Ois A, et al. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke 2009;40:3197-3201.
34. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58:373-379.
35. Bouwman FH, van der Flier WM, Schoonenboom NS, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007;69:1006-1011.
36. Toledo JB, Brettschneider J, Grossman M, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 2012;124:23-35.
37. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013;368:117-127.
38. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013;368:107-116.
39. Ragno M, Pianese L, Morroni M, et al. "CADASIL coma" in an Italian homozygous CADASIL patient: comparison with clinical and MRI findings in age-matched heterozygous patients with the same G528C NOTCH3 mutation. Neurol Sci 2013;34:1947-1953.
40. Vinciguerra C, Rufa A, Bianchi S, et al. Homozygosity and severity of phenotypic presentation in a CADASIL family. Neurol Sci 2014;35:91-93.